share_log

Avalo Therapeutics | D: Filing D

Avalo Therapeutics | D: Filing D

Avalo Therapeutics | D：發行公告
SEC announcement ·  04/10 05:02
牛牛AI助理已提取核心訊息
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.
Avalo Therapeutics, Inc.已向美國證券交易委員會提交了D表格的證券豁免發行通知，其中指出了與企業合併交易相關的股票和證券發行的新通知。此次發行始於2024年3月27日，在總髮行額爲199,976,986美元中，已售出130,601,986美元。這些證券的發行與涉及雅典項目合併子公司、AlmataBio, Inc.和第二雅典項目合併子公司的合併有關。Avalo Therapeutics拒絕透露發行人規模，並根據《證券法》第506（b）條申請豁免。該公司總部位於馬里蘭州羅克維爾，從事生物技術行業，並在文件中列出了幾位執行官和董事。尚未報告任何銷售佣金，但據估計，發現者的費用約爲6,937,500美元。此次發行的收益不用於向指定執行官、董事或發起人支付超出其正常薪酬的款項。
Avalo Therapeutics, Inc.已向美國證券交易委員會提交了D表格的證券豁免發行通知，其中指出了與企業合併交易相關的股票和證券發行的新通知。此次發行始於2024年3月27日，在總髮行額爲199,976,986美元中，已售出130,601,986美元。這些證券的發行與涉及雅典項目合併子公司、AlmataBio, Inc.和第二雅典項目合併子公司的合併有關。Avalo Therapeutics拒絕透露發行人規模，並根據《證券法》第506（b）條申請豁免。該公司總部位於馬里蘭州羅克維爾，從事生物技術行業，並在文件中列出了幾位執行官和董事。尚未報告任何銷售佣金，但據估計，發現者的費用約爲6,937,500美元。此次發行的收益不用於向指定執行官、董事或發起人支付超出其正常薪酬的款項。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。